Aerovate
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 51
- Market Cap
- $54.2M
- Introduction
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
Jade Biosciences Advances JADE101 Anti-APRIL Antibody for IgA Nephropathy with $300M Funding
Jade Biosciences completed a reverse merger and raised approximately $300 million, providing financial runway through 2027 to advance its autoimmune disease pipeline.
Pharmaceutical Industry Faces Widespread Layoffs Amid Patent Cliffs and Economic Uncertainty
• Major pharmaceutical companies including Pfizer, Novartis, and Takeda have implemented significant workforce reductions over the past year due to patent cliffs and economic pressures. • Unlike previous trends, current layoffs are heavily impacting R&D departments, marking a shift from traditional commercial-focused cuts and reflecting the industry's evolving outsourcing landscape. • Contract Research Organizations (CROs) are benefiting from the industry shift, absorbing displaced talent and gaining additional business as pharmaceutical companies restructure their operations.